PD-1 Protein (AA 25-167) (Fc Tag)
-
- Target See all PD-1 (PDCD1) Proteins
- PD-1 (PDCD1) (Programmed Cell Death 1 (PDCD1))
- Protein Type
- Recombinant
- Biological Activity
- Active
- Protein Characteristics
- AA 25-167
-
Origin
- Human
-
Source
- HEK-293 Cells
- Purification tag / Conjugate
- This PD-1 protein is labelled with Fc Tag.
- Sequence
- AA 25-167
- Characteristics
- This protein carries a human IgG1 Fc tag at the C-terminus. The protein has a calculated MW of 42.6 kDa. The protein migrates as 50-66 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.
- Purity
- >95 % as determined by SDS-PAGE.
- Sterility
- 0.22 μm filtered
- Endotoxin Level
- Less than 0.1 EU per μg by the LAL method.
- Top Product
- Discover our top product PDCD1 Protein
-
-
- Restrictions
- For Research Use only
-
- Format
- Lyophilized
- Buffer
- PBS, pH 7.4
- Handling Advice
- Please avoid repeated freeze-thaw cycles.
- Storage
- -20 °C
- Storage Comment
- No activity loss was observed after storage at: In lyophilized state for 1 year (4 °C), After reconstitution under sterile conditions for 3 months (-70 °C).
-
-
Tumor-selective blockade of CD47 signaling with a CD47/PD-L1 bispecific antibody for enhanced anti-tumor activity and limited toxicity." in: Cancer immunology, immunotherapy : CII, (2020) (PubMed).
: "Comprehensive in vitro characterization of PD-L1 small molecule inhibitors. ..." in: Scientific reports, Vol. 9, Issue 1, pp. 12392, (2019) (PubMed).
: "PD-L1:CD80 Cis-Heterodimer Triggers the Co-stimulatory Receptor CD28 While Repressing the Inhibitory PD-1 and CTLA-4 Pathways." in: Immunity, Vol. 51, Issue 6, pp. 1059-1073.e9, (2019) (PubMed).
: "Agonist redirected checkpoint, PD1-Fc-OX40L, for cancer immunotherapy." in: Journal for immunotherapy of cancer, Vol. 6, Issue 1, pp. 149, (2018) (PubMed).
: "Artificial T Cell Mimetics to Combat Melanoma Tumor Growth." in: American journal of advanced drug delivery, Vol. 6, Issue 1, pp. 21-32, (2018) (PubMed).
: "A Novel PD-L1-targeting Antagonistic DNA Aptamer With Antitumor Effects." in: Molecular therapy. Nucleic acids, Vol. 5, Issue 12, pp. e397, (2016) (PubMed).
: "
-
Tumor-selective blockade of CD47 signaling with a CD47/PD-L1 bispecific antibody for enhanced anti-tumor activity and limited toxicity." in: Cancer immunology, immunotherapy : CII, (2020) (PubMed).
-
- Target
- PD-1 (PDCD1) (Programmed Cell Death 1 (PDCD1))
- Alternative Name
- PD-1 (PDCD1 Products)
- Synonyms
- CD279 Protein, PD-1 Protein, PD1 Protein, SLEB2 Protein, hPD-1 Protein, hPD-l Protein, Ly101 Protein, Pdc1 Protein, programmed cell death 1 Protein, PDCD1 Protein, Pdcd1 Protein
- Background
- Programmed cell death protein 1 (PD-1) is also known as CD279 and PDCD1, is a type I membrane protein and is a member of the extended CD28/CTLA-4 family of T cell regulators. PDCD1 is expressed on the surface of activated T cells, B cells, macrophages, myeloid cells and a subset of thymocytes. PD-1 has two ligands, PD-L1 and PD-L2, which are members of the B7 family. PD-L1 is expressed on almost all murine tumor cell lines, including PA1 myeloma, P815 mastocytoma, and B16 melanoma upon treatment with IFN-γ. PD-L2 expression is more restricted and is expressed mainly by DCs and a few tumor lines. PD1 inhibits the T-cell proliferation and production of related cytokines including IL-1, IL-4, IL-10 and IFN-γ by suppressing the activation and transduction of PI3K/AKT pathway. In addition, coligation of PD1 inhibits BCR-mediating signal by dephosphorylating key signal transducer. In vitro, treatment of anti-CD3 stimulated T cells with PD-L1-Ig results in reduced T cell proliferation and IFN-γ secretion. Monoclonal antibodies targeting PD-1 that boost the immune system are being developed for the treatment of cancer.
- Molecular Weight
- 42.1 kDa
- NCBI Accession
- NP_005009
- Pathways
- Cancer Immune Checkpoints
-